Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer.
Deniz Can GuvenSaadettin KilickapGurkan GunerHakan TabanOmer DizdarPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2019)
We think that rare adverse events like de novo psoriasis are important considering the expanding role of these agents; their timely recognition and treatment are important in the management of cancer patients.